Credit Suisse’s Argos Therapeutics, Inc. ARGS Stock Holding History

Credit Suisse’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,004	Closed	-$3K	–	4281
2017 Q4	$3K	Buy	+1,004	New	+$3.37K	﹤0.01%	3958
2015 Q4	–	Sell	-1,598	Closed	-$154K	–	4560
2015 Q3	$154K	Sell	1,598 -194	-11%	-$23K	﹤0.01%	4015
2015 Q2	$245K	Sell	1,792 -366	-17%	-$58.5K	﹤0.01%	4122
2015 Q1	$384K	Buy	2,158 +80	+4%	+$13.9K	﹤0.01%	3715
2014 Q4	$415K	Buy	+2,078	New	+$374K	﹤0.01%	3844
2014 Q2	–	Sell	-757	Closed	-$151K	–	5018
2014 Q1	$151K	Buy	+757	New	+$151K	﹤0.01%	4438

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Credit Suisse's ARGS Position: Q1 2018 in Review

Credit Suisse sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 1,004 shares — an estimated $3K sold.

Credit Suisse first reported a position in ARGS in Q1 2014 and held it in 6 quarters. The position peaked at $415K in Q4 2014. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

Credit Suisse reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Credit Suisse sold 1,004 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $3K.
Credit Suisse first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 6 quarters.
Credit Suisse's Argos Therapeutics, Inc. position peaked at $415K in Q4 2014.
16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Credit Suisse's 13F filing for Q1 2018, filed 15 May 2018.